|
Navidea Biopharmaceuticals, Inc. (NAVB) Valoración de DCF
US | Healthcare | Biotechnology | AMEX
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Navidea Biopharmaceuticals, Inc. (NAVB) Bundle
¿Busca evaluar el valor intrínseco de Navidea Biopharmaceuticals, Inc.? Nuestra calculadora DCF (NAVB) integra datos del mundo real con características de personalización integrales, lo que le permite refinar sus pronósticos y mejorar sus opciones de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2018 |
AY2 2019 |
AY3 2020 |
AY4 2021 |
AY5 2022 |
FY1 2023 |
FY2 2024 |
FY3 2025 |
FY4 2026 |
FY5 2027 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .3 | .0 | .9 | .5 | .1 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -91.75 | 3337.57 | -41.91 | -87.65 | -30.33 | -30.33 | -30.33 | -30.33 | -30.33 |
| EBITDA | -10.8 | -10.8 | -10.6 | -11.5 | -13.9 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -3363.29 | -40641.69 | -1162.91 | -2164.89 | -21134.32 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .2 | .1 | .2 | .2 | .1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 46.63 | 542.91 | 20.83 | 37.41 | 145.95 | 60.97 | 60.97 | 60.97 | 60.97 | 60.97 |
| EBIT | -11.0 | -11.0 | -10.8 | -11.7 | -14.0 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -3409.91 | -41184.6 | -1183.74 | -2202.3 | -21280.27 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 4.3 | 1.0 | 2.7 | 4.2 | 2.0 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .9 | 3.0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 6.56 | 3386.2 | 326.48 | 17.5 | 0.95961 | 45 | 45 | 45 | 45 | 45 |
| Inventories | .0 | -.9 | .2 | .2 | .4 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0.00031005733 | -3386.2 | 18.56 | 28.44 | 650.92 | 9.4 | 9.4 | 9.4 | 9.4 | 9.4 |
| Accounts Payable | .4 | 1.1 | 1.2 | 1.4 | 2.1 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 131.69 | 4177.88 | 126.96 | 267.41 | 3233.01 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | -.1 | -.4 | -.3 | -.4 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -14.32 | -213.01 | -45.23 | -61.98 | -594.57 | -64.31 | -64.31 | -64.31 | -64.31 | -64.31 |
| Tax Rate, % | 0.000019766549 | 0.000019766549 | 0.000019766549 | 0.000019766549 | 0.000019766549 | 0.000019766549 | 0.000019766549 | 0.000019766549 | 0.000019766549 | 0.000019766549 |
| EBITAT | -11.0 | -11.0 | -10.7 | -11.7 | -14.0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -10.5 | -10.2 | -14.1 | -8.7 | -13.7 | -1.7 | .0 | .0 | .0 | .0 |
| WACC, % | 44.93 | 45.05 | 44.71 | 45.05 | 45.05 | 44.96 | 44.96 | 44.96 | 44.96 | 44.96 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | 0 | |||||||||
| Equity Value | -2 | |||||||||
| Diluted Shares Outstanding, MM | 31 | |||||||||
| Equity Value Per Share | -0.05 |
What You Will Get
- Editable Forecast Inputs: Easily adjust key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Navidea Biopharmaceuticals, Inc.'s (NAVB) financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template automatically computes Net Present Value (NPV) and intrinsic value for your convenience.
- Customizable and Professional: A sleek Excel model that can be tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and optimizing your time.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation frameworks tailored for Navidea Biopharmaceuticals, Inc. (NAVB).
- WACC Calculator: Includes a pre-designed Weighted Average Cost of Capital sheet with adjustable parameters.
- Customizable Forecast Assumptions: Easily update growth projections, capital expenditures, and discount rates.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Navidea Biopharmaceuticals, Inc. (NAVB).
- Interactive Dashboard and Charts: Visual representations to summarize essential valuation metrics for streamlined analysis.
How It Works
- Step 1: Download the prebuilt Excel template featuring Navidea Biopharmaceuticals, Inc. (NAVB) data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including Navidea's intrinsic value.
- Step 5: Make well-informed investment choices or create reports based on the outputs.
Why Choose This Calculator for Navidea Biopharmaceuticals, Inc. (NAVB)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Valuation: Observe immediate updates to Navidea's valuation as you modify the inputs.
- Preloaded Data: Comes with Navidea’s actual financial figures for swift evaluations.
- Preferred by Experts: Utilized by investors and analysts for making strategic decisions.
Who Should Use This Product?
- Healthcare Students: Explore biopharmaceutical valuation techniques and apply them using real-world data.
- Researchers: Integrate advanced models into your studies or clinical research.
- Investors: Evaluate your investment strategies and analyze valuation outcomes for Navidea Biopharmaceuticals, Inc. (NAVB).
- Market Analysts: Enhance your analysis with a customizable, pre-built valuation model tailored for biopharmaceuticals.
- Entrepreneurs: Understand how public biopharmaceutical companies like Navidea are assessed in the market.
What the Template Contains
- Historical Data: Includes Navidea Biopharmaceuticals, Inc.'s (NAVB) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Navidea Biopharmaceuticals, Inc.'s (NAVB) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital relevant to Navidea Biopharmaceuticals, Inc. (NAVB).
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions for Navidea Biopharmaceuticals, Inc. (NAVB).
- Quarterly and Annual Statements: A complete breakdown of Navidea Biopharmaceuticals, Inc.'s (NAVB) financials.
- Interactive Dashboard: Visualize valuation results and projections for Navidea Biopharmaceuticals, Inc. (NAVB) dynamically.